Search Result

Pathways Recommended:	JAK/STAT Signaling

Results for "

JAK-STAT

" in MedChemExpress (MCE) Product Catalog:

By Targets:	JAK (33) STAT (32) Acyltransferase (1) Akt (6) Apoptosis (22) Atg8/LC3 (3) Autophagy (7) Bcl-2 Family (3) Bcr-Abl (1) c-Myc (1) Caspase (4) Cathepsin (1) CDK (2) Deubiquitinase (1) Discoidin Domain Receptor (1) Dopamine Receptor (1) EGFR (2) Endogenous Metabolite (2) ERK (1) Ferroptosis (2) FLT3 (1) Glucocorticoid Receptor (1) HBV (1) HCV (1) IFNAR (3) Interleukin Related (6) IRAK (1) Keap1-Nrf2 (1) MEK (1) MicroRNA (2) Neurokinin Receptor (1) NF-κB (9) Oxidative Phosphorylation (1) p38 MAPK (4) p62 (3) PARP (2) PERK (1) Phosphatase (3) PI3K (4) PROTACs (3) Protease Activated Receptor (PAR) (1) Raf (1) Ras (2) Reactive Oxygen Species (ROS) (3) Reference Standards (4) RET (1) STING (1) TAM Receptor (1) TGF-β Receptor (1) TNF Receptor (1) Tyrosinase (1) Wnt (2)
By Research Areas:	Cancer (41) Cardiovascular Disease (7) Endocrinology (1) Infection (2) Inflammation/Immunology (20) Metabolic Disease (1) Neurological Disease (3)
Oligonucleotides:	Antisense Oligonucleotides (2)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Targets Recommended: STAT JAK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N1447

Ganoderic acid A 5+ Cited Publications	Apoptosis Autophagy Endogenous Metabolite	Cancer
Ganoderic acid A can inhibit of the *JAK-STAT3* signaling pathway, also inhibit proliferation, viability, ROS.

HY-109182

Lorpucitinib JNJ-64251330	JAK STAT	Inflammation/Immunology
Lorpucitinib (JNJ-64251330) is an orally active pan-JAK inhibitor with good enteric selectivity and safety. Lorpucitinib can inhibit the *JAK/STAT* pathway and reduce the levels of inflammatory biomarkers in serum. Lorpucitinib can be used in the research of familial adenomatous polyposis and gastrointestinal inflammatory diseases .

HY-132601A

Cobomarsen sodium MRG-106 sodium	MicroRNA	Cancer
Cobomarsen sodium is an oligonucleotide inhibitor of miR-155. Cobomarsen sodium inhibits multiple gene pathways associated with cell survival (including *JAK/STAT, MAPK/ERK* and PI3K/AKT). Cobomarsen sodium can be used for the research of B-cell lymphoma .

HY-128450

JAK-STAT-IN-1	JAK STAT	Inflammation/Immunology Cancer
JAK-STAT-IN-1 (compound 1) is a selective *JAK-STAT* inhibitor. JAK-STAT-IN-1 can be used for the research of autoimmune disorder .

HY-111275

WP-1034	JAK STAT Apoptosis Caspase PARP	Cancer
WP-1034 is a *JAK-STAT* inhibitor with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). WP-1034 blocks activation of Stat 3 and 5. WP-1034 induces cell cycle arrest and triggers apoptosis. WP-1034 can be used for AML research .

HY-N12473

25-Deacetylcucurbitacin A	JAK	Inflammation/Immunology
25-Deacetylcucurbitacin A is a Cucurbitane-Type triterpenoid and has the potential to be an anti-cancer agent and JAK/STAT3 signaling pathway inhibitor .

HY-N1447R

Ganoderic acid A (Standard)	Reference Standards Apoptosis Autophagy Endogenous Metabolite	Cancer
Ganoderic acid A (Standard) is the analytical standard of Ganoderic acid A. This product is intended for research and analytical applications. Ganoderic acid A can inhibit of the JAK-STAT3 signaling pathway, also inhibit proliferation, viability, ROS.

HY-103438A

BIBU1361 dihydrochloride	Apoptosis Autophagy Akt	Cancer
BIBU1361 dihydrochloride induces apoptosis and inhibits autophagy. BIBU1361 inhibits pro-survival pathways Akt/mTOR and *gp130/JAK/STAT3, and decreased levels of pro-inflammatory cytokine IL-6* .

HY-103438

BIBU1361	Apoptosis Akt Autophagy	Cancer
BIBU1361 induces apoptosis and inhibits autophagy. BIBU1361 inhibits pro-survival pathways Akt/mTOR and *gp130/JAK/STAT3, and decreased levels of pro-inflammatory cytokine IL-6* .

HY-E70789

BCR-RET Recombinant Human Active Protein Kinase	RET	Others
BCR-RET Recombinant Human Active Protein Kinase is a BCR-RET fusion protein in hematopoietic malignancies. BCR-RET overactivates the Ras-ERK pathway, in addition to JAK/STAT3 and PI3K/AKT pathways .

HY-N0781

Linderalactone 1 Publications Verification	Apoptosis	Cancer
Linderalactone is an important sesquiterpene lactone isolated from Lindera aggregata. Linderalactone inhibits cancer growth by modulating the expression of apoptosis-related proteins and inhibition of JAK/STAT signalling pathway. Linderalactone also inhibits the proliferation of the lung cancer A-549 cells with an IC₅₀ of 15 µM .

HY-115734

Phenylpyropene C S14-95	Acyltransferase	Inflammation/Immunology
Phenylpyropene C (S14-95), a *JAK/STAT* pathway inhibitor, can inhibit IFN-γ mediated expression of the reporter gene (IC₅₀=5.4~10.8 μM). Phenylpyropene C also is an inhibitor of acyl-CoA, with an IC₅₀ of 16.0 μM .

HY-132601

Cobomarsen MRG-106	MicroRNA	Cancer
Cobomarsen (MRG-106) is an oligonucleotide inhibitor of miR-155. Cobomarsen inhibits multiple gene pathways associated with cell survival (including *JAK/STAT, MAPK/ERK* and PI3K/AKT). Cobomarsen can be used for the research of B-cell lymphoma .

HY-N2409

Delphinidin chloride 1 Publications Verification	Apoptosis EGFR JAK STAT	Cardiovascular Disease Cancer
Delphinidin chloride is an anthocyanin isolated from berries and red wine. Delphinidin chloride exhibits endothelium-dependent vasodilation and anticancer activity. Delphinidin chloride also modulates *JAK/STAT3* and MAPK signaling, thereby inducing apoptosis in HCT116 cells. Delphinidin chloride is also a potent inhibitor of EGFR (IC₅₀: 1.3 μM), shutting down downstream signaling cascades .

HY-N0781R

Linderalactone (Standard)	Reference Standards Apoptosis	Cancer
Linderalactone (Standard) is the analytical standard of Linderalactone. This product is intended for research and analytical applications. Linderalactone is an important sesquiterpene lactone isolated from Lindera aggregata. Linderalactone inhibits cancer growth by modulating the expression of apoptosis-related proteins and inhibition of JAK/STAT signalling pathway. Linderalactone also inhibits the proliferation of the lung cancer A-549 cells with an IC₅₀ of 15 μM .

HY-116035

Nimbolide 1 Publications Verification	Wnt NF-κB CDK Apoptosis	Cancer
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and CDK4/CDK6 kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-107595

SD-1008 1 Publications Verification	JAK STAT Apoptosis	Cancer
SD-1008 is a potent JAK inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances apoptosis induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway .

HY-149257

HAT-SIL-TG-1&AT	JAK STAT	Cancer
HAT-SIL-TG-1&AT is a Janus tyrosine kinase (JAK) inhibitor with antitumor effects. HAT-SIL-TG-1&AT is the hypoxia-activated prodrug, witch inhibits *JAK-STAT* signaling in tumor tissue. And HAT-SIL-TG-1&AT inhibits HEL cells proliferation and downregulated phosphorylated *STAT3/5* under hypoxic conditions .

HY-N10623

5-epi-Arvestonate A	Tyrosinase	Cancer
5-epi-Arvestonate A is a sesquiterpenoid isolated from the whole plants of Seriphidium transiliense. 5-epi-Arvestonate A promotes melanogenic production by activating the transcription of microphthalmia-associated transcription factor (MITF) and tyrosinase family genes. 5-epi-Arvestonate A inhibits the expression of IFN-γ-chemokine through the JAK/STAT signaling pathway in immortalized human keratinocyte (HaCaT) cells .

HY-150538

STAT3-IN-12 1 Publications Verification	STAT Apoptosis	Cancer
STAT3-IN-12 is a potent *STAT3* signal inhibitor that can inhibit IL-6 induced JAK/STAT3 signalling pathway activation. STAT3-IN-12 inhibits cancer cell growth, migration, and induce cell apoptosis as well as cycle arrest. STAT3-IN-12 can be used in cancer-related research, such as hepatocellular carcinoma (HCC) and oesophageal carcinoma .

HY-153190A

W1131 TFA	Ferroptosis STAT	Cancer
W1131 TFA is a potent STAT3 inhibitor that induces ferroptosis. W1131 inhibits cancer progression in subcutaneous xenograft, organoid, and PDX models of gastric cancer. W1131 effectively alleviates cancer cell chemoresistance to 5-FU (HY-90006). W1131 regulates the cell cycle, DNA damage response, and oxidative phosphorylation, including the IL6-JAK-STAT3 pathway and the ferroptosis pathway .

HY-N2409R

Delphinidin chloride (Standard)	Apoptosis EGFR JAK STAT Reference Standards	Cardiovascular Disease Cancer
Delphinidin (chloride) (Standard) is the analytical standard of Delphinidin (chloride). This product is intended for research and analytical applications. Delphinidin chloride is an anthocyanin isolated from berries and red wine. Delphinidin chloride exhibits endothelium-dependent vasodilation and anticancer activity. Delphinidin chloride also modulates JAK/STAT3 and MAPK signaling, thereby inducing apoptosis in HCT116 cells. Delphinidin chloride is also a potent inhibitor of EGFR (IC50: 1.3 μM), shutting down downstream signaling cascades .

HY-116035R

Nimbolide (Standard)	Wnt NF-κB CDK Apoptosis	Cancer
Nimbolide (Standard) is the analytical standard of Nimbolide. This product is intended for research and analytical applications. Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and CDK4/CDK6 kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-153190

W1131	Oxidative Phosphorylation STAT Ferroptosis	Cancer
W1131 is a potent *STAT3* inhibitor, triggering ferroptosis. W1131 suppresses cancer progression in gastric cancer cell subcutaneous xenograft model, organoids model, and PDX model. W1131 effectively alleviates chemical resistance of cancer cells to 5-FU (HY-90006). W1131 regulates cell cycle, DNA damage response, and oxidative phosphorylation, including *IL6-JAK-STAT3* pathway and ferroptosis pathway .

HY-W063968

RO8191 Maximum Cited Publications 22 Publications Verification CDM-3008; RO4948191	IFNAR JAK STAT HCV HBV	Infection
RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and *JAK/STAT* phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC₅₀ of 200 nM for HCV replicon . RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity .

HY-163151

JE-133	PI3K Akt p38 MAPK	Neurological Disease Inflammation/Immunology
JE-133 is an optically active isochromane-2H-chromene conjugate. JE-133 exhibits antioxidant and anti-inflammatory activities. JE-133 is a neuroprotective agent that effectively inhibits neuronal oxidative damage associated with PI3K/Akt and MAPK signaling pathways. JE-133 can also inhibit lipopolysaccharide (LPS) (HY-D1056)-induced neuroinflammation by regulating *JAK/STAT* and Nrf2 signaling pathways .

HY-167692

JI069	STAT	Others
JI069 is a novel JAK-STAT inhibitor that demonstrates potent activity in suppressing Th1, Th2, and Th17 differentiation while promoting iTreg differentiation. JI069 effectively inhibits STAT3 activation as well as the activation of other STATs, including STAT1, STAT5, and STAT6. JI069 has shown significant therapeutic potential in alleviating symptoms of collagen-induced arthritis in mice while inhibiting cytokine production from T cells and the phosphorylation of STAT3 in synovial cells.

HY-175771

STAT3-IN-46	STAT c-Myc Bcl-2 Family Interleukin Related JAK	Cancer
STAT3-IN-46 is a selective and orally active inhibitor of signal transducer and activator of transcription 3 (STAT3) (K_D = 323.3 nM). STAT3-IN-46 directly binds to the SH2 domain of the STAT3 and inhibits IL-6/JAK/STAT3 signaling pathway (IC₅₀ = 0.87 μM) and downregulates c-Myc and Bcl-2 levels. STAT3-IN-46 can be used for the research of cancer, such as triple-negative breast cancer .

HY-176876

Glucocorticoid receptor/IL-6-IN-1	Glucocorticoid Receptor Interleukin Related JAK STAT	Inflammation/Immunology
Glucocorticoid receptor/IL-6-IN-1 (Compound 35) is a selective dual inhibitor targeting the glucocorticoid receptor (GR) and IL-6 signaling pathway (IC₅₀ values of 120 nM and 59 nM, respectively). Glucocorticoid receptor/IL-6-IN-1 inhibits IL-6-induced JAK/STAT3 phosphorylation, blocking inflammatory cytokine transcription. Glucocorticoid receptor/IL-6-IN-1 is promising for research of inflammatory diseases like rheumatoid arthritis and asthma .

HY-P99143

Anti-Mouse NK1.1 Antibody (PK136)	Neurokinin Receptor NF-κB STAT	Inflammation/Immunology
Anti-Mouse NK1.1 Antibody (PK136) is an anti-mouse NK1.1 IgG2a monoclonal antibody. Anti-Mouse NK1.1 Antibody (PK136) can deplete natural killer (NK) cells. Anti-Mouse NK1.1 Antibody (PK136) inhibits the *JAK-STAT* and NF-κB signaling pathways. Anti-Mouse NK1.1 Antibody (PK136) can be used for research on inflammation conditions such as non-alcoholic steatohepatitis (NASH) .

HY-120920

UNC9995	Dopamine Receptor	Inflammation/Immunology
UNC9995 is a β-arrestin2-biased agonist of dopamine receptor Drd2. UNC9995 inhibits NLRP3 inflammasome activation by enhancing β-arrestin2-NLRP3 interaction, thus prevents neuronal degeneration. Futhermore, UNC9995 activates the Drd2/β-arrestin2 signaling to prevent inflammation-related genes transcription-induced by *JAK/STAT3*. UNC9995 improves depressive behavior in mouse model, and improves astrocytes dysfunctions .

HY-145923

Osunprotafib 5 Publications Verification ABBV-CLS-484	Phosphatase STAT JAK	Cancer
Osunprotafib (ABBV-CLS-484) is an orally active and selective active site PTPN1 (IC₅₀: 2.5 nM) and PTPN2(IC₅₀: 1.8 nM) inhibitor. Osunprotafib has 6-8-fold weaker activity on PTPN9 and no detectable activity on SHP-1 or SHP-2. Osunprotafib increases the sensitivity of human cancer cell lines to IFNγ. Osunprotafib generates robust anti-tumor immunity by enhancing JAK-STAT signalling and reducing T cell dysfunction .

HY-145923B

Osunprotafib hydrochloride ABBV-CLS-484 hydrochloride	Phosphatase	Inflammation/Immunology Cancer
Osunprotafib (ABBV-CLS-484) hydrochloride is an orally active and selective active site PTPN1 (IC₅₀: 2.5 nM) and PTPN2(IC₅₀: 1.8 nM) inhibitor. Osunprotafib hydrochloride has 6-8-fold weaker activity on PTPN9 and no detectable activity on SHP-1 or SHP-2. Osunprotafib hydrochloride increases the sensitivity of human cancer cell lines to IFNγ. Osunprotafib hydrochloride generates robust anti-tumor immunity by enhancing JAK-STAT signalling and reducing T cell dysfunction .

HY-170772

Dual Cathepsin L/JAK-IN-1	p38 MAPK STAT Interleukin Related Cathepsin JAK	Inflammation/Immunology
Dual Cathepsin L/JAK-IN-1 (Compound A8) is a dual inhibitor of Cathepsin L (CTSL) and JAK, with IC₅₀ values of 0.68 μM, 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for CTSL, JAK1/2/3, and TYK2, respectively. Dual Cathepsin L/JAK-IN-1 effectively blocks the activation of the MAPK, NF-κB, and *JAK/STAT* signaling pathways, leading to significant anti-inflammatory therapeutic effects. Dual Cathepsin L/JAK-IN-1 can be used in research on acute lung injury (ALI) .

HY-151262

JAK-IN-23 1 Publications Verification	JAK STING NF-κB STAT	Inflammation/Immunology
JAK-IN-23 is an orally active double inhibitor of JAK/STAT and NF-κB. JAK-IN-23 can inhibit JAK1/2/3 with IC₅₀ values of 8.9 nM, 15 nM and 46.2 nM, respectively. JAK-IN-23 has potent inhibitory activities against interferon-stimulated genes (ISG) and NF-κB pathways with IC₅₀ values of 3.3 nM and 150.7 nM, respectively. JAK-IN-23 has great anti-inflammatory that decreases the release of various proinflammatory factors. JAK-IN-23 can be used for the research of inflammatory bowel disease (IBD) .

HY-N0818

Chikusetsusaponin Iva 2 Publications Verification Calenduloside F	Keap1-Nrf2	Infection Metabolic Disease Endocrinology Cancer
Chikusetsusaponin IVa is an orally active protein kinase activator. Chikusetsusaponin IVa binds to YAP with a K_D value of 0.388 mM. Chikusetsusaponin IVa reduces inflammatory mediators (IL-6, IL-10, COX-2) expression, NO production, promotes ROS generation, induces Apoptosis, inhibits MAPK, TAZ, and regulates Nrf2, *JAK/STAT. Chikusetsusaponin Iva has anti-H9N2 AIV* and anti-endometrial cancer activities. Chikusetsusaponin Iva shows anti-inflammatory, hepatoprotective and osteoprotective effects .

HY-178500

WCY-8-67	Deubiquitinase Apoptosis STAT JAK Akt PI3K	Cancer
WCY-8-67 is an orally active and selective USP5 inhibitor, with an IC₅₀ value of 1.33 μM. WCY-8-67 induces apoptosis and suppresses *JAK/STAT3* and PI3K/AKT signaling pathways in vitro. WCY-8-67 inhibits proliferation of AE-positive AML cells, induces G1 phase arrest and differentiation of AML cells. WCY-8-67 demonstrates potent anti-leukemic efficacy in mice. WCY-8-67 can be used for the study of acute myeloid leukemia .

HY-18200A

Atopaxar hydrochloride E5555 hydrochloride; ER-172594-00 hydrochloride	Protease Activated Receptor (PAR) JAK Apoptosis	Cardiovascular Disease Cancer
Atopaxar hydrochloride (E5555 hydrochloride) is the hydrochloride salt form of Atopaxar (HY-18200). Atopaxar hydrochloride is an orally active, selective and reversible antagonist for thrombin receptor protease-activated receptor-1 (PAR-1). Atopaxar hydrochloride is the inhibitor for Janus kinase 1 (JAK1) and JAK2, which inhibits the *JAK-STAT* with EC₅₀ of 5.90 μM in A549. Atopaxar hydrochloride inhibits the cell viability of A549 (IC₅₀=7.02 μM), arrests the cell cycle at G1 phase and induces apoptosis. Atopaxar hydrochloride exhibits antiplatelet and antitumor activities. Atopaxar hydrochloride can be used for the research of atherothrombotic disease .

HY-177515

IRAK4 modulator-2	IRAK STAT JAK NF-κB	Inflammation/Immunology
IRAK4 modulator-2 (Compound 5) is a selective dual Interleukin-1 Receptor Associated Kinase 4 (IRAK4) and IRAK1 inhibitor with IC₅₀ values of 0.005 μM and 0.97 μM, erespectively. IRAK4 modulator-2 blocks IRAK-mediated signaling pathways (e.g., JAK-STAT, NF-κB pathways), reduces the production of pro-inflammatory cytokines (e.g., IL-1, TNF), and exerts anti-inflammatory activity. IRAK4 modulator-2 is promising for research of autoimmune diseases and inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel disease .

HY-119009

TM-233	JAK STAT NF-κB Bcl-2 Family	Cancer
TM-233 is an inhibitor of the *JAK/STAT* and NF-κB signaling pathways, exhibiting significant antitumor activity. TM-233 reduces the expression of the anti-apoptotic protein Mcl-1 by inhibiting the phosphorylation of JAK2 and *STAT3, and regulates its transcription by directly binding to the Mcl-1* gene promoter. Additionally, TM-233 prevents the translocation of NF-κB from the cytoplasm to the nucleus by inhibiting its DNA-binding activity, thereby reducing nuclear NF-κB expression. TM-233 shows potential in overcoming Bortezomib (HY-10227) resistance and can be applied in research related to multiple myeloma .

HY-N7694

Isotoosendanin 1 Publications Verification	TGF-β Receptor JAK STAT Apoptosis	Inflammation/Immunology Cancer
Isotoosendanin is an orally active TGFβR1 inhibitor and abrogating its kinase activity (IC₅₀ = 6732 nM). Isotoosendanin inhibits the *JAK/STAT3* signaling pathway by directly targeting SHP-2, enhancing its stability, and reducing its ubiquitination. Isotoosendanin inhibits TGF-β-induced reduces the migration, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. Isotoosendanin exhibits anti-tumor efficacy in TNBC xenograft models and A549 xenograft tumors. Isotoosendanin exhibits significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema tests. Isotoosendanin can be used for the study of non-small cell lung cancer (NSCLC), TNBC and inflammation .

HY-117548

UNC1062 2 Publications Verification	TAM Receptor Apoptosis p38 MAPK ERK PI3K Akt JAK STAT	Cardiovascular Disease Cancer
UNC1062 is a highly selective tyrosine kinase (MERTK) inhibitor with an IC₅₀ of 1.1 nM (Morrison K_i = 0.33 nM). UNC1062 exhibits good selectivity for the TAM family (TYRO3 IC₅₀ = 60 nM, AXL IC₅₀ = 85 nM). UNC1062 exhibits significant anti-proliferative effects and induces apoptosis in various cancer models (such as melanoma, gastric cancer, and acute myeloid leukemia). UNC1062 inhibits multiple pathways, including MAPK/ERK, PI3K/AKT and *JAK/STAT* and affects the motility of head and neck squamous cell carcinoma (HNSCC) cells through the RhoA signaling pathway. UNC1062 inhibits macrophage efferocytosis, and it suitable for research on atherosclerosis .

HY-N0705

Curculigoside 5+ Cited Publications	JAK STAT NF-κB	Neurological Disease Inflammation/Immunology Cancer
Curculigoside is the main saponin in C. orchioide, exerts significant antioxidant, anti-osteoporosis, antidepressant and neuroprotection effects. Curculigoside possesses significant anti-arthritic effects in vivo and in vitro via regulation of the *JAK/STAT/NF-κB* signaling pathway .

HY-153858

PHI-501	Raf Discoidin Domain Receptor MEK TNF Receptor Interleukin Related JAK STAT Ras	Cancer
PHI-501 is a dual inhibitor targeting RAF/DDR. PHI-501 exhibits significant anti-proliferative effects in melanoma cell lines and significantly inhibits the colony formation of drug-resistant cells. PHI-501 strongly inhibits ERK and AKT phosphorylation. PHI-501 downregulates the gene sets in drug-resistant cells of TNFA-NFKB, *IL6-JAK-STAT3, and KRAS* signaling pathways as well as the epithelial-mesenchymal transition (EMT) signaling pathways. PHI-501 demonstrates significant anti-tumor effects in the SK-MEL3DR xenograft model. PHI-501 can be used for research on the problem of drug resistance in melanoma .

HY-164393

ON044580	JAK Bcr-Abl Apoptosis	Cancer
ON044580, an α-benzoyl styryl benzyl sulfide, is a potent and non-ATP-competitive JAK2 kinase inhibitor with IC₅₀s of 1.23 μM, 1.09 μM for WT and V617F mutant JAK2, respectively. ON044580 inhibits the JAK2 kinase activity either by binding to the STAT-5 binding domain of JAK2 or by binding to an allosteric site. ON044580 exerts its antiproliferative effect in JAK2 ^V617F-positive leukemic cells. ON044580 effectively induces apoptosis of Imatinib (HY-15463)-resistant chronic myelogenous leukemia (CML) cells. ON044580 also inhibits both WT and T315I mutant forms of the BCR-ABL kinase. ON044580 has the potential for myeloproliferative disorders typified by aberrant JAK/STAT signaling .

HY-N0705R

Curculigoside (Standard)	Reference Standards JAK STAT NF-κB	Neurological Disease Inflammation/Immunology Cancer
Curculigoside (Standard) is the analytical standard of Curculigoside. This product is intended for research and analytical applications. Curculigoside is the main saponin in C. orchioide, exerts significant antioxidant, anti-osteoporosis, antidepressant and neuroprotection effects. Curculigoside possesses significant anti-arthritic effects in vivo and in vitro via regulation of the JAK/STAT/NF-κB signaling pathway .

HY-13559A

Atiprimod dimaleate Azaspirane dimaleate; SKF 106615-12 dimaleate; SKF 106615A12 dimaleate	STAT Apoptosis Caspase Interleukin Related Autophagy Reactive Oxygen Species (ROS) Atg8/LC3 p62 JAK	Cardiovascular Disease Inflammation/Immunology Cancer
Atiprimod (Azaspirane) (dimaleate) is a *STAT3* inhibitor with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of IL-6 and VEGF by inhibiting the phosphorylation of signal transducer and activator of *STAT3. Atiprimod blocks the JAK-STAT* signaling pathway by inhibiting the phosphorylation of JAK2 and JAK3. Atiprimod also inhibits cell proliferation, induces cell cycle arrest, and induces autophagy and apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2α/ATF4/CHOP axis and inhibiting the nuclear translocation of *STAT3/NF-κB*. Atiprimod shows great anti-tumor activities in tumor xenograft mouse models. Atiprimod can be used for the study of pituitary adenoma, breast cancer, multiple myeloma and acute myeloid leukemia (AML) .

HY-13559

Atiprimod Azaspirane ; SKF 106615-12; SKF 106615A12	STAT Apoptosis Autophagy Reactive Oxygen Species (ROS) Caspase Bcl-2 Family p62 Atg8/LC3 PARP NF-κB PERK JAK	Cardiovascular Disease Inflammation/Immunology Cancer
Atiprimod (Azaspirane) is a *STAT3* inhibitor with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of IL-6 and VEGF by inhibiting the phosphorylation of signal transducer and activator of *STAT3. Atiprimod blocks the JAK-STAT* signaling pathway by inhibiting the phosphorylation of JAK2 and JAK3. Atiprimod also inhibits cell proliferation, induces cell cycle arrest, and induces autophagy and apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2α/ATF4/CHOP axis and inhibiting the nuclear translocation of *STAT3/NF-κB*. Atiprimod shows great anti-tumor activities in tumor xenograft mouse models. Atiprimod can be used for the study of pituitary adenoma, breast cancer, multiple myeloma and acute myeloid leukemia (AML) .

HY-110102

Atiprimod hydrochloride Azaspirane hydrochloride; SKF 106615-12 hydrochloride; SKF 106615	JAK STAT Apoptosis Autophagy Reactive Oxygen Species (ROS) Caspase Atg8/LC3 p62	Cardiovascular Disease Inflammation/Immunology Cancer
Atiprimod (Azaspirane) hydrochloride is a *STAT3* inhibitor with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of IL-6 and VEGF by inhibiting the phosphorylation of signal transducer and activator of *STAT3. Atiprimod blocks the JAK-STAT* signaling pathway by inhibiting the phosphorylation of JAK2 and JAK3. Atiprimod also inhibits cell proliferation, induces cell cycle arrest, and induces autophagy and apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2α/ATF4/CHOP axis and inhibiting the nuclear translocation of *STAT3/NF-κB*. Atiprimod shows great anti-tumor activities in tumor xenograft mouse models. Atiprimod can be used for the study of pituitary adenoma, breast cancer, multiple myeloma and acute myeloid leukemia (AML) .

HY-172581

Clifutinib	FLT3 Apoptosis Ras p38 MAPK PI3K Akt JAK STAT	Cancer
Clifutinib is an orally active and selective internal tandem duplication mutation of FMS-like tyrosine kinase 3 (FLT3-ITD) inhibitor with an IC₅₀ value of 15.1 nM. Clifutinib exerts strong antiproliferative effects on FLT3-ITD acute myeloid leukemia (AML) cell lines (MV-4-11: IC₅₀ = 1.5 nM; MOLM-13: IC₅₀ = 1.4 nM). Clifutinib inhibits the activity of FLT3-ITD kinase and blocks the downstream RAS/MAPK, PI3K/AKT, and JAK/STAT5 signaling pathways of FLT3. Clifutinib induces apoptosis of acute myeloid leukemia (AML) cells with FLT3-ITD mutations. Clifutinib demonstrates significant antitumor efficacy in mice bearing MV-4-11 or MOLM-13 xenografts. Clifutinib is promising for research of relapsed/refractory FLT3-ITD-positive acute myeloid leukemia .

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library

612 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 612 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Cat. No.	Product Name	Target	Research Area